DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

Blood

Volumn 125, Issue 12, 2015, Pages 1922-1931

  Arribas, Alberto J ^a   Rinaldi, Andrea ^a   Mensah, Afua A ^a   Kwee, Ivo ^a,b   Cascione, Luciano ^a,c   Robles, Eloy F ^d   Martinez Climent, Jose A ^d   Oscier, David ^e   Arcaini, Luca ^f   Baldini, Luca ^g   Marasca, Roberto ^h   Thieblemont, Catherine ⁱ   Briere, Josette ⁱ   Forconi, Francesco ^j,k   Zamò, Alberto ^l   Bonifacio, Massimiliano ^l   Mollejo, Manuela ^m   Facchetti, Fabio ⁿ   Dirnhofer, Stephan ^o   Ponzoni, Maurilio ^p   Bhagat, Govind ^q   Piris, Miguel A ^r   Gaidano, Gianluca ^s   Zucca, Emanuele ^c   Rossi, Davide ^s   Bertoni, Francesco ^a,c   more..

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b DALLE MOLLE INSTITUTE FOR ARTIFICIAL INTELLIGENCE IDSIA   (Switzerland)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d UNIVERSITY OF NAVARRA   (Spain)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^k UNIVERSITY OF SIENA   (Italy)

^l UNIVERSITY OF VERONA   (Italy)

^m HOSPITAL VIRGEN DE LA SALUD   (Spain)

ⁿ UNIVERSITY OF BRESCIA   (Italy)

^o UNIVERSITY OF BASEL   (Switzerland)

^p SAN RAFFAELE HOSPITAL   (Italy)

^q Department of Medicine   (United States)

^r HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^s UNIVERSITY OF EASTERN PIEDMONT   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CACNB2 GENE; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL FEATURE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REPRESSION; GENETIC ASSOCIATION; HTRA1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IGHV1 GENE; KLF4 GENE; LYMPHOMA CELL LINE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; NOTCH2 GENE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SPLENIC MARGINAL ZONE LYMPHOMA; TUMOR SUPPRESSOR GENE; CELL TRANSFORMATION; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; GENETICS; KAPLAN MEIER METHOD; LYMPHOMA, B-CELL, MARGINAL ZONE; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; SPLENIC NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84925357071     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-596247     Document Type: Article

References (51)

1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
2. Rinaldi A, Mian M, Chigrinova E, et al. Genomewide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5):1595-1604.
3. Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood. 2010;116(9):1479-1488.
4. Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209(9):1537-1551.
5. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med. 2012;209(9):1553-1565.
6. Parry M, Rose-Zerilli MJ, Gibson J, et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS ONE. 2013;8(12):e83244.
7. Martínez N, Almaraz C, Vaqué JP, et al. Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia. 2014;28(6):1334-1340.
8. Chambwe N, Kormaksson M, Geng H, et al. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014;123(11):1699-1708.
9. Krajnović M, Jovanović MP, Mihaljević B, et al. Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease. Clin Transl Sci. 2014;7(5):384-390.
10. Giachelia M, Bozzoli V, D'Alò F, et al. Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. J Mol Diagn. 2014;16(4):467-476.
11. Jiang Y, Hatzi K, Shaknovich R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood. 2013;121(21):4271-4279.
12. James LI, Barsyte-Lovejoy D, Zhong N, et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol. 2013;9(3):184-191.
13. Kim W, Bird GH, Neff T, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9(10):643-650.
14. Zhang J, Jima D, Moffitt AB, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood. 2014;123(19):2988-2996.
15. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495.
16. Rinaldi A, Mensah AA, Kwee I, et al. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol. 2013;163(2):194-204.
17. Fresquet V, Robles EF, Parker A, et al. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginalzone lymphoma. Br J Haematol. 2012;158(6):712-726.
18. Rinaldi A, Forconi F, Arcaini L, et al. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. Br J Haematol. 2010;151(5):435-439.
19. Lacrima K, Valentini A, Lambertini C, et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol. 2005;16(7):1169-1176.
20. Kalac M, Scotto L, Marchi E, et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood. 2011;118(20):5506-5516.
21. Bibikova M, Le J, Barnes B, et al. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics. 2009;1(1):177-200.
22. Shamir R, Maron-Katz A, Tanay A, et al. EXPANDER - an integrative program suite for microarray data analysis. BMC Bioinformatics. 2005;6:232.
23. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
25. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-1740.
26. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-2504.
27. Delaleu N, Nguyen CQ, Tekle KM, Jonsson R, Peck AB. Transcriptional landscapes of emerging autoimmunity: transient aberrations in the targeted tissue's extracellular milieu precede immune responses in Sjögren's syndrome. Arthritis Res Ther. 2013;15(5):R174.
28. Holemon H, Korshunova Y, Ordway JM, et al. MethylScreen: DNA methylation density monitoring using quantitative PCR. Biotechniques. 2007;43(5):683-693.
29. Arcaini L, Lazzarino M, Colombo N, et al Integruppo Italiano Linfomi. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643-4649.
30. Arribas AJ, Gómez-Abad C, Sánchez-Beato M, et al. Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling. Mod Pathol. 2013;26(7):889-901.
31. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118(18):4930-4934.
32. Novak U, Rinaldi A, Kwee I, et al. The NF-KB negative regulator TNFAIP3 (A20) is commonly inactivated by somatic mutations and genomic deletions in marginal zone B-cell lymphomas. Blood. 2009;113(20):4918-4921.
33. Trøen G, Nygaard V, Jenssen TK, et al. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn. 2004;6(4):297-307.
34. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185.
35. Cao Q, Yu J, Dhanasekaran SM, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008;27(58):7274-7284.
36. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003;22(20):5323-5335.
37. Kanduri M, Sander B, Ntoufa S, et al. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. Epigenetics. 2013;8(12):1280-1288.
38. Guan H, Xie L, Leithäuser F, et al. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood. 2010;116(9):1469-1478.
39. Valencia-Hipólito A, Hernandez-Atenógenes M, Vega GG, et al. Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma. Leuk Lymphoma. 2014;55(8):1806-1814.
40. Li Z, Zhao J, Li Q, et al. KLF4 promotes hydrogenperoxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Cell Stress Chaperones. 2010;15(6):905-912.
41. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36(5):494-504.
42. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 1995;15(5):2672-2681.
43. Ozaki T, Nakagawara A, Nagase H. RUNX family participates in the regulation of p53-dependent DNA damage response. Int J Genomics. 2013;2013:271347.
44. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 1994;266(5189):1376-1380.
45. Derissen EJ, Beijnen JH, Schellens JH. Concise drug review: azacitidine and decitabine. Oncologist. 2013;18(5):619-624.
46. Boi M, Gaudio E, Bonetti P, et al. The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015.
47. Mensah AA, Kwee I, Gaudio E, et al. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. Oncotarget. 2014.
48. Vesci L, Bernasconi E, Milazzo FM, et al. Preclinical antitumor activity of ST7612AA1: a novel second generation oral histone deacetylase (HDAC) inhibitor. Oncotarget. 2014.
49. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94.
50. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406-3413.
51. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115(3):475-480.